Regeneron Pharmaceuticals Inc

More Details of Regeneron Pharmaceuticals Inc Company

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.

Company Info

Company codeREGN

Company nameRegeneron Pharmaceuticals Inc

IPO dateApr 02, 1991

Founded at1988

CEODr. Leonard S. Schleifer, M.D., Ph.D

Number of employees15106

Security typeOrdinary Share

Fiscal year-endApr 02

Address777 Old Saw Mill River Road

CityTARRYTOWN

Stock exchangeNASDAQ Global Select Consolidated

CountryUnited States of America

Postal code10591

Phone17813705000

Websitehttps://www.regeneron.com/

Company codeREGN

IPO dateApr 02, 1991

Founded at1988

Company Executives

Name

Name/Position

Position

Shareholding

Change

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

782.24K

-11.33%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

695.45K

--

Dr. Neil Stahl, Ph.D.

Executive Vice President - Research and Development

54.50K

-1.39%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

53.40K

+3.80%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

42.00K

+2.78%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.89K

+6.02%

Mr. George L. Sing

Independent Director

29.90K

+0.56%

Mr. Arthur F. (Art) Ryan

Independent Director

17.67K

+0.95%

Mr. Christopher R. Fenimore

Chief Financial Officer, Senior Vice President - Finance

16.35K

+6.24%

Ms. Marion E. McCourt

Executive Vice President - Commercial

14.37K

+9.94%

Name

Name/Position

Position

Shareholding

Change

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

782.24K

-11.33%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

695.45K

--

Dr. Neil Stahl, Ph.D.

Executive Vice President - Research and Development

54.50K

-1.39%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

53.40K

+3.80%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

42.00K

+2.78%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.89K

+6.02%

Revenue Breakdown

Currency: USDUpdate time: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

EYLEA

4.77B

33.57%

Sanofi

4.53B

31.91%

Bayer

1.50B

10.55%

EYLEA HD

1.20B

8.46%

Libtayo

787.30M

5.54%

Other

1.42B

9.97%

No Data

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

EYLEA

4.77B

33.57%

Sanofi

4.53B

31.91%

Bayer

1.50B

10.55%

EYLEA HD

1.20B

8.46%

Libtayo

787.30M

5.54%

Other

1.42B

9.97%

Shareholder

Update time: Fri, Feb 21

Shareholder Statistics

Type

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

8.59%

Fidelity Management & Research Company LLC

7.41%

BlackRock Institutional Trust Company, N.A.

5.30%

JP Morgan Asset Management

4.88%

State Street Global Advisors (US)

4.49%

Other

69.32%

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

8.59%

Fidelity Management & Research Company LLC

7.41%

BlackRock Institutional Trust Company, N.A.

5.30%

JP Morgan Asset Management

4.88%

State Street Global Advisors (US)

4.49%

Other

69.32%

Type

Shareholder

Proportion

Investment Advisor

47.88%

Investment Advisor/Hedge Fund

33.06%

Research Firm

2.77%

Pension Fund

2.59%

Bank and Trust

2.16%

Hedge Fund

2.07%

Individual Investor

1.66%

Sovereign Wealth Fund

1.15%

Insurance Company

0.08%

Other

6.57%

Institutional Shareholding

Update time: Sun, Jan 19

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

2516

100.27M

93.27%

-268.91K

2024Q4

2581

100.17M

93.15%

-475.65K

2024Q3

2505

99.81M

90.67%

-1.99M

2024Q2

2479

100.87M

93.10%

+570.24K

2024Q1

2440

99.77M

92.44%

+388.23K

2023Q4

2406

98.50M

91.94%

-617.06K

2023Q3

2358

98.79M

92.52%

-1.71M

2023Q2

2360

99.25M

92.00%

-1.42M

2023Q1

2366

99.66M

92.70%

-1.10M

2022Q4

2333

99.78M

93.16%

-1.62M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

9.24M

8.59%

-32.55K

-0.35%

Dec 31, 2024

Fidelity Management & Research Company LLC

7.97M

7.41%

-2.08M

-20.68%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

5.70M

5.3%

+193.71K

+3.52%

Dec 31, 2024

JP Morgan Asset Management

5.24M

4.88%

-524.97K

-9.10%

Dec 31, 2024

State Street Global Advisors (US)

4.83M

4.49%

-70.17K

-1.43%

Dec 31, 2024

Capital International Investors

4.74M

4.41%

+1.39M

+41.55%

Dec 31, 2024

Capital World Investors

2.78M

2.58%

-1.52M

-35.35%

Dec 31, 2024

Geode Capital Management, L.L.C.

2.43M

2.26%

+155.37K

+6.84%

Dec 31, 2024

Dodge & Cox

2.32M

2.16%

+9.38K

+0.41%

Dec 31, 2024

Invesco Capital Management (QQQ Trust)

2.24M

2.08%

+29.93K

+1.36%

Feb 28, 2025

Related ETFs

Update time: Sun, Apr 6

Name

Proportion

Tema Neuroscience and Mental Health ETF

7.56%

Invesco Nasdaq Biotechnology ETF

7.22%

ProShares Ultra Nasdaq Biotechnology

6.8%

Simplify Health Care ETF

6.73%

iShares Biotechnology ETF

6.22%

VanEck Biotech ETF

4.94%

Invesco Biotechnology & Genome ETF

4.65%

iShares Genomics Immunology and Healthcare ETF

4%

Franklin Genomic Advancements ETF

3.51%

Invesco QQQ Low Volatility ETF

3.35%

Tema Neuroscience and Mental Health ETF

Proportion7.56%

Invesco Nasdaq Biotechnology ETF

Proportion7.22%

ProShares Ultra Nasdaq Biotechnology

Proportion6.8%

Simplify Health Care ETF

Proportion6.73%

iShares Biotechnology ETF

Proportion6.22%

VanEck Biotech ETF

Proportion4.94%

Invesco Biotechnology & Genome ETF

Proportion4.65%

iShares Genomics Immunology and Healthcare ETF

Proportion4%

Franklin Genomic Advancements ETF

Proportion3.51%

Invesco QQQ Low Volatility ETF

Proportion3.35%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

Feb 04, 2025

REGN.NB Interim Cash Dividend of gross USD 0.88 paid on Mar 20, 2025 going ex on Feb 20, 2025

Feb 20, 2025

Mar 20, 2025

Feb 20, 2025

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

557.910USD

Regeneron Pharmaceuticals Inc

557.910

Overview

Company